Go Search

EDUCATE PATIENTS ABOUT THE VOLUNTARY FORTEO PATIENT REGISTRY AND ENCOURAGE THEM TO ENROLL

The FORTEO Patient Registry plays an important role in monitoring the long-term safety of FORTEO, including the potential risk of osteosarcoma

Patient participation is voluntary and involves the following 3 steps:

Patient completes the brief information on the pre-enrollment card.

After the pre-enrollment card is received, the patient will be mailed a one-page informed consent form, a short registration form, and a $5 token of appreciation for the patient's time in completing the forms.*

Patient returns the informed consent and registration forms to the voluntary FORTEO Patient Registry.

That's it. Once the patient has returned the consent and registration forms, the patient will not be contacted further without his/her consent.

Patients can pre-enroll in the voluntary FORTEO Patient Registry by completing a form found within any of the following:

  • Their FORTEO prescription
  • Their FORTEO Patient Starter Kit
  • The voluntary FORTEO Patient Registry Brochure

Or by:

*We want you to know that RTI International, a non-profit research company, is conducting this safety study on behalf of Eli Lilly and Company, the makers of FORTEO. Your patient's personal information, including any data that can identify patients, will not be shared with Eli Lilly and Company or anyone outside the research team without the patient's permission.

INDICATIONS AND USAGE

  • FORTEO is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, and for the treatment of men and women with osteoporosis associated with sustained, systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture
  • High risk for fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy

FORTEO is administered as a
20-microgram once-daily dose and is available in a 2.4-mL prefilled delivery device for subcutaneous injection over 28 days.

SAFETY INFORMATION AND BOXED WARNING

expand